JAKJAK

Back to Disease

Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE

Definition of Remission in Rheumatoid Arthritis & Likelihood with Advanced Therapies

What is the ORAL Surveillance study and how can it be applied to clinical practice?

What is the safety profile of upadacitinib across indications?

Variability in JAK Inhibition Specificity & Its Clinical Implications

How is upadacitinib dosed across rheumatologic indications?

Describe the Mechanism of Action of Upadacitinib

Provide immunologic rationale for JAK directed therapy in rheumatic disease

Describe JAK-STAT signaling in inflammation

Download the app and start using it now.

Download on the App Store

GET IT ON Google Play